Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PRLD |
---|---|---|
09:32 ET | 222 | 3.79 |
09:34 ET | 100 | 3.7 |
10:12 ET | 2900 | 3.75 |
10:35 ET | 100 | 3.7225 |
11:36 ET | 529 | 3.75 |
11:47 ET | 100 | 3.78 |
12:25 ET | 300 | 3.75 |
12:36 ET | 102 | 3.7844 |
12:56 ET | 1000 | 3.75 |
01:30 ET | 100 | 3.75 |
02:15 ET | 901 | 3.75 |
03:00 ET | 100 | 3.75 |
03:02 ET | 100 | 3.75 |
03:48 ET | 100 | 3.765 |
03:50 ET | 100 | 3.765 |
03:52 ET | 100 | 3.79 |
03:57 ET | 400 | 3.76 |
03:59 ET | 3549 | 3.75 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Prelude Therapeutics Inc | 195.5M | -2.0x | --- |
Elevation Oncology Inc | 200.8M | -3.4x | --- |
Achieve Life Sciences Inc | 188.9M | -4.1x | --- |
Rezolute Inc | 186.6M | -5.0x | --- |
Boundless Bio Inc | 204.5M | 0.0x | --- |
Compass Therapeutics Inc. | 184.4M | -3.7x | --- |
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $207.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 54.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.55 |
EPS | $-1.88 |
Book Value | $4.32 |
P/E Ratio | -2.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.